TickerGuard
Buy Day today: Poor (58) Mixed market breadth · today: CPI (July)
ATR

AptarGroup Inc

Healthcare · Medical Instruments & Supplies

134.80$ +0.8% vs. previous close Closing price · As of: Aug 11, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of AptarGroup Inc (ATR). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — ATR
Segment Q1 2025 Q2 2025 Q1 2026 Q2 2026
Pharma $409.5M 46.1% $442.6M 45.8% $438.6M 44.6% $458.2M 44.6%
Beauty $305.7M 34.5% $334.8M 34.7% $363.6M 37.0% $367.5M 35.8%
Closures $172.1M 19.4% $188.6M 19.5% $180.7M 18.4% $200.9M 19.6%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by region

Revenue by region — ATR
Segment Q1 2025 Q2 2025 Q1 2026 Q2 2026
Europe $438.6M 49.4% $476.0M 49.3% $510.9M 52.0% $521.0M 50.8%
Domestic $282.5M 31.8% $309.7M 32.1% $279.8M 28.5% $292.0M 28.4%
Asia $93.7M 10.6% $104.1M 10.8% $106.2M 10.8% $128.4M 12.5%
Latin America $72.5M 8.2% $76.1M 7.9% $86.0M 8.7% $85.1M 8.3%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Remaining performance obligations

Remaining performance obligations are the part of the business already sold but not yet delivered and therefore not yet booked as revenue. In subscription and project businesses it points the way earlier than revenue does.

Remaining performance obligations — ATR
As of Remaining performance obligations
Q1 2021 $523.0K
Q4 2020 $536.0K
Q3 2020 $487.0K
Q2 2020 $410.0K
Q1 2020 $432.0K
Q4 2019 $515.0K
Q3 2019 $504.0K
Q2 2019 $590.0K

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?